Yen Bo LinDr. Taiwan

Yen Bo LinDr.
Dr. Albert (Yen‑Bo) Lin is an attending physician in the Division of Endocrinology and Metabolism at National Taiwan University Hospital, Bei‑Hu Branch, and a certified diabetes educator. He received his M.D. from Fu Jen Catholic University and completed residency and fellowship training at National Taiwan University Hospital. Dr. Lin holds a Master of Public Health from the Johns Hopkins Bloomberg School of Public Health, with concentrations in epidemiology, biostatistics, and public health informatics. His research focuses on diabetes epidemiology, thyroid cancer genomics, and autoimmune endocrine disorders. He has published in Head & Neck, Scientific Reports, the European Thyroid Journal, and the Journal of Diabetes Investigation. Dr. Lin’s clinical and academic work emphasizes evidence‑based endocrine care and the integration of population health approaches into chronic disease management.

22 MARCH

Time Session
14:00
15:30
ESROC–MEMS Joint Symposium
Digital Endocrinology, Wearables, and Future Therapeutics in Asia
Waye Hann KangMalaysia Moderator
Yi-Sun YangTaiwan Moderator Impaired Fasting Glucose and Musculoskeletal DisordersThe Continuum of Glycemic Dysregulation and Musculoskeletal Health: From Impaired Fasting Glucose to Established Diabetes. As the global medical community transitions into the "Next ERA" of endocrinology, there is an urgent need to broaden our focus beyond traditional microvascular and macrovascular complications toward the pervasive, yet often neglected, musculoskeletal (MS) burden associated with dysglycemia. While the debilitating effects of established Type 2 Diabetes Mellitus (T2DM) on physical function are well-documented, emerging clinical evidence suggests that the musculoskeletal system is an early "silent" target of metabolic injury, with pathological changes manifesting as early as the Impaired Fasting Glucose (IFG) stage. This presentation explores the MS burden across the full glycemic spectrum, highlighting how the transition from normoglycemia to IFG, and ultimately to T2DM, correlates with a progressive increase in chronic pain, structural tissue damage, and functional disability.
  • Continuous Glucose Monitoring (CGM) in Asia: Behavior Change, Physician Workflow, and New Care Models
    Jun-Sing WangTaiwan Speaker Continuous Glucose Monitoring (CGM) in Asia: Behavior Change, Physician Workflow, and New Care Models
  • AI and Digital Diabetes Care: Awareness, Utilisation and Perspectives from Malaysia
    Chee Keong SeeMalaysia Speaker AI and Digital Diabetes Care: Awareness, Utilisation and Perspectives from Malaysia
  • Next-Generation Biomarkers for Thyroid Cancer and Endocrine Tumors
    Yen Bo LinTaiwan Speaker Next-Generation Biomarkers for Thyroid Cancer and Endocrine Tumors
  • Future Endocrine Therapeutics in Southeast Asia: From Super Mono, Dual to Triple Incretin Agonists and Beyond
    Siew Hui FooMalaysia Speaker Future Endocrine Therapeutics in Southeast Asia: From Super Mono, Dual to Triple Incretin Agonists and BeyondThe role of incretin-based therapy is taking the front seat globally due to the high prevalence of obesity, diabetes and related complications worldwide. Similar scene is expected to take place in South East Asia that is facing the escalating burden of obesity driving up the already high burden of type 2 diabetes especially in the younger population despite consisting of relatively small countries in areas and population. This poses adverse socio-economic impact to the region due to increased risk of premature complications and death among the young in a region that is largely still developing. The arrival of incretin-based therapy into South East Asia since the first daily glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection in 2010 has picked up its pace in the last 5 years with the entry of weekly GLP-1 RA injection, oral GLP-1 RA and GLP-1 RA / GIP (glucose-dependent insulinotropic polypeptide) injection. This lecture will address the evidence behind its efficacy, tolerability as well as cardiovascular effects of these agents in the Asian populations. The future shift to the more potent high-dose GLP-1 receptor mono-agonist, dual, triple incretin receptor multi-agonist and beyond as these agents are approved for treatment for the twin epidemics of type 2 diabetes, obesity and related complications will be discussed along with the challenges especially on unequitable access, healthcare disparities, unregulated dispensing and the importance of a strengthened health system with multi-sectoral cooperation at the regional level to mitigate these issues.
  • Discussion
103